PDF AgendaRegister TodayEvent Updates

Richard Vellacott

BiologIC Technologies

An authentic, passionate and entrepreneurial leader, Richard inspires transformational change through the alignment of purposeful vision, outstanding talent and quality capital. He delivers high growth to life science and technology companies from private start-ups to global businesses that are publicly listed in the UK and the US. He creates significant value through executive leadership, vision and strategy, commercialization of science, capital market expertise, cultural and organizational change and building scalable capability. Richard is co-founder, CEO and Chair of BiologIC Technologies Limited. BiologIC’s vision is to integrate Industry 4.0 technologies to solve enormous challenges faced by humanity (feeding 9.8 billion people by 2050, mitigating climate change and mitigating the threat of diseases) in an environmentally sustainable, economically accessible way. In seven valuable years as interim CEO, deputy CEO, CFO, COO and Company Secretary of Horizon Discovery Group plc, Richard was instrumental in growing the business from an emerging private company of £3m revenue in 2012 to a recognized global leader in gene editing delivering revenue of £60m at a valuation of £350m. Richard delivered one of the most successful ever Life Science listings on AIM raising £68.6m in a heavily oversubscribed IPO at the top of its valuation range within 3 months, fundraisings in the UK and the US, four acquisitions and hostile bid defense. Richard stepped down from the Board of Horizon in January 2019 to pursue other interests. From 2010 to 2012, Richard was Vice President, Finance at CSR plc, a dual listed FTSE 250 company with $1bn of revenues. Previously, he was a director in Deloitte’s life sciences practice, working with leading companies such as AstraZeneca, Vectura, CAT, Acambis and Abcam. He specialized in capital market transactions including numerous IPOs, M&As and fundraisings on AIM, Main Market and NASDAQ. Richard is a qualified chartered accountant with a first class honours degree in biological sciences from Durham University. He is a life science thought leader, has advised the European Committee on funding for life science companies and is a mentor of aspiring talent.